We are a molecular diagnostics company developing and commercializing a pipeline of proprietary products for the screening and diagnosis of cancer.
Our products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients.
Our lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A..
Our technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories.
We are an international company with operations in Europe and the U.S.A.
Our products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients.
Our lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A..
Our technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories.
We are an international company with operations in Europe and the U.S.A.
Location: United States, California, San Diego
Employees: 51-200
Phone: +1 858-429-6199
Founded date: 1998
Investors 3
Mentions in press and media 16
| Date | Title | Description |
| 30.08.2024 | A New Dawn in Autoimmune and Cancer Detection: NIH Grants Propel Innovation | In the realm of medical innovation, funding is the lifeblood that fuels discovery. Recently, two biopharmaceutical companies received significant grants from the National Institutes of Health (NIH), marking a pivotal moment in the fight aga... |
| 29.08.2024 | Precision Epigenomics Receives $2M Award from National Institutes of Health | Precision Epigenomics (PRNewsfoto/Precision Epigenomics) This award will lead to the development of EPISEEK-MPE, a multi-cancer detection test, using pleural fluid to detect cancer. TUCSON, Ariz., Aug. 29, 2024 /PRNewswire-PRWeb/ -- Precisi... |
| 07.03.2024 | Europe Colorectal Cancer Screening and Diagnostic Market Analysis and Forecast 2023-2033, Featuring Key Players Epigenomics, Mainz Biomed and Novigenix | - |
| 14.03.2023 | Startup Showcase: Epigenomics – Early Cancer Detection through Molecular Diagnostics | Epigenomics is a Berlin-based startup that focuses on developing and manufacturing a pipeline of products for the diagnosis of cancer. Epigenomics’ mission is to develop diagnostic tests that can detect cancer at early stages before symptom... |
| 10.11.2021 | Epigenomics AG publishes financial results for the first nine months 2021 | DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter Results Epigenomics AG publishes financial results for the first nine months 2021 10.11.2021 / 08:00 The issuer is solely responsible for the content of this ann... |
| 10.11.2021 | PRESS RELEASE : Epigenomics AG publishes financial results for the first nine months 2021 | DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/Quarter Results Epigenomics AG publishes financial results for the first nine months 2021 2021-11-10 / 08:00 The issuer is solely responsible for the content of this ann... |
| 07.10.2021 | Epigenomics AG: EVP of Finance Albert Weber leaves the Company | DGAP-News: Epigenomics AG / Key word(s): Personnel Epigenomics AG: EVP of Finance Albert Weber leaves the Company 07.10.2021 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG: EVP of Finance Alber... |
| 02.09.2021 | Epigenomics : ???????New study in the BMC Cancer journal shows that Epi proColon(R) is an effective method to increase CRC screening rates in medically underserved populations | DGAP-News: Epigenomics AG / Key word(s): Study results/Study ???????New study in the BMC Cancer journal shows that Epi proColon(R) is an effective method to increase CRC screening rates in medically underserved populations 02.09.2021 / 13:4... |
| 24.08.2021 | PRESS RELEASE : Epigenomics AG: Securities prospectus for the issuance of a mandatory convertible bond in the amount of up to EUR 16.5 million approved by BaFin | DGAP-News: Epigenomics AG / Key word(s): Issue of Debt/Corporate Action Epigenomics AG: Securities prospectus for the issuance of a mandatory convertible bond in the amount of up to EUR 16.5 million approved by BaFin 2021-08-24 / 16:16 The ... |
| 17.08.2021 | DGAP-Adhoc : Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance | DGAP-Ad-hoc: Epigenomics AG / Key word(s): Strategic Company Decision/Change in Forecast Epigenomics AG: Execution of a Biobank Sale Agreement and Update of Guidance 17-Aug-2021 / 21:00 CET/CEST Disclosure of an inside information acc. to A... |
Show more